518. Comparable Outcomes of Remdesivir and Sotrovimab among High-risk Patients with Mild to Moderate COVID-19 During the Omicron BA.1 Surge

BACKGROUND: Two independent placebo-controlled clinical trials conducted prior to SARS-CoV-2 Omicron demonstrated that sotrovimab and remdesivir reduced hospitalization among high-risk outpatients with mild to moderate COVID-19. However, their effectiveness have not been directly compared. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Chesdachai, Supavit, Rivera (O'Connor), Christina G, Mara, Kristin, Teaford, Hiliary R, Suarez, Maria Gonzalez, Larsen, Jennifer J, Ganesh, Ravindra, Tulledge-Scheitel, Sidna, Razonable, Raymund R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678075/
http://dx.doi.org/10.1093/ofid/ofad500.587

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678075/
http://dx.doi.org/10.1093/ofid/ofad500.587

Ejemplares similares